Pharmaceutical Technology

NOVEMBER 9, 2022

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Patients may receive this therapy regardless of PD-L1 expression or tumour histology.

Chemotherapy 52

Chemotherapy FDA Adverse Reactions 52

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Who is Likely to Have an Adverse Reaction to Fluoride, and What are the Symptoms?

Compounding 116

Compounding Adverse Reactions Chemotherapy Labelling 116

The Thyroid Pharmacist

JULY 8, 2022

As of 2018, there have been at least two active studies underway to gain more definitive results, the GRASS (Graves’ Disease Selenium Supplementation) and the CATALYST (The Chronic Autoimmune Thyroiditis Quality of Life Selenium Trial). Those with a CBS gene mutation have difficulty breaking down selenium.

Dosage 59

Dosage Immunization Adverse Reactions Insurance 59